The neonatal Fc receptor in cancer FcRn in cancer.

Abstract

Since the neonatal IgG Fc receptor (FcRn) was discovered, it was found to be involved in immunoglobulin recycling and biodistribution, immune complexes routing, antigen presentation, humoral immune response, and cancer immunosurveillance. The latest data show that FcRn plays a part in cancer pathophysiology. In various types of cancers, such as lung and colorectal cancer, FcRn has been described as an early marker for prognosis. Dysregulation of FcRn expression by cancer cells allows them to increase their metabolism, and this process could be exploited for passive targeting of cytotoxic drugs. However, the roles of this receptor depend on whether the studied cell population is the tumor tissue or the infiltrating cells, bringing forward the need for further studies.

• Authors: Diana Cadena Castaneda, Guillaume Brachet, Caroline Goupille, Lobna Ouldamer, Valérie Gouilleux-Gruart
• Journal: Cancer medicine (Cancer Med) Vol. 9 Issue 13 Pg. 4736-4742 (07 2020) ISSN: 2045-7634 [Electronic] United States
• PMID: 32368865 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Chemical References

• Biomarkers, Tumor
• Histocompatibility Antigens Class I
• Receptors, Fc
• Fc receptor, neonatal

Topics

• Animals
• Biomarkers, Tumor
• Carcinogenesis (genetics)
• Down-Regulation
• Gene Expression Regulation, Neoplastic
• Histocompatibility Antigens Class I (genetics, metabolism, physiology)
• Humans
• Killer Cells, Natural (immunology)
• Mice
• Monitoring, Immunologic
• Neoplasms (immunology, metabolism, mortality)
• Prognosis
• Receptors, Fc (genetics, metabolism, physiology)